Acceptability of 'as needed' biologic therapy in psoriasis: insights from a multistakeholder mixed-methods study.

These data indicate that 'as needed' biologic therapy in psoriasis is acceptable for both patients and clinicians. Formal assessment of clinical effectiveness and cost-effectiveness is warranted to enable the real-world potential of this approach to be realized.